Claims
- 1. A method for treating a neoplasm which comprises administering to a mammal in need of such treatment, an oncolytic agent having an anti-neoplastic effect in combination with a protein kinase C inhibitor, wherein the protein kinase C inhibitor enhances the anti-neoplastic effect of the oncolytic agent.
- 2. The method of claim 1 wherein the protein kinase C inhibitor is an inhibitor of the β isozyme of protein kinase C and is a bis-indolylmaleimide or a macrocyclic bis-indolylmaleimide.
- 3. The method of claim 1 wherein the protein kinase C inhibitor is isozyme selective and where the isozyme selectivity is selected from the group consisting of beta-1 and beta-2 isozymes.
- 4. The method of claim 3 wherein the protein kinase C inhibitor has the following formula:
5
- 5. The method of claim 4 wherein the protein kinase C inhibitor has the following formula:
6
- 6. The method of claim 4 wherein the protein kinase C inhibitor has the following formula:
7
- 7. The method of claim 4, wherein the protein kinase C inhibitor comprises (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or its pharmaceutically acceptable acid salt.
- 8. The method of claim 1, wherein the oncolytic agent is selected from the group consisting of Ara-c, VP-16, cis-platinum, adriamycin, 2-chloro-2-deoxyadenosine, 9-β-D-arabinosyl-2-fluoroadenine, and glucocorticoids.
- 9. A method for treating a neoplasm which comprises administering to a mammal in need of such treatment, γ-irradiation having an anti-neoplastic effect in combination with a protein kinase C inhibitor, wherein the protein kinase C inhibitor enhances the anti-neoplastic effect of γ-irradiation.
- 10. The method of claim 9 wherein the protein kinase C inhibitor is an inhibitor of the β isozyme of protein kinase C and is a bis-indolylmaleimide or a macrocyclic bis-indolylmaleimide.
- 11. The method of claim 9 wherein the protein kinase C inhibitor is isozyme selective and where the isozyme selectivity is selected from the group consisting of beta-1 and beta-2 isozymes.
- 12. The method of claim 11 wherein the protein kinase C inhibitor has the following formula:
8
- 13. The method of claim 12 wherein the protein kinase C inhibitor has the following formula:
9
- 14. The method of claim 12 wherein the protein kinase C inhibitor has the following formula:
10
- 15. The method of claim 12, wherein the protein kinase C inhibitor comprises (S)-3 ,4-[N, N′-1,1 ′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or its pharmaceutically acceptable acid salt.
Parent Case Info
[0001] This application claims the priority benefits of the U.S. Provisional application Serial No. 60/016,658 filed May 1, 1996.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60016658 |
May 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08841738 |
Apr 1997 |
US |
Child |
09758020 |
Jan 2001 |
US |